Immunovant (IMVT) reported a fiscal Q1 net loss Monday of $0.71 per diluted share, wider than the net loss of $0.60 a year earlier.
Analysts polled by FactSet expected a loss of $0.68.
As expected, no revenue for the quarter ended June 30 was reported.
As of June 30, the company said it had $598.9 million in cash and or cash equivalents on hand, which will likely finance operations through its Graves' disease trial readout anticipated in 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.